NSE: AARTIDRUGS - Aarti Drugs Limited

Доходность за полгода: +9.86%
Сектор: Healthcare

График акции Aarti Drugs Limited


О компании

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene.

Подробнее
It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Выручка 18.06
EBITDA 2.67
P/E 8.91
P/S 0.6976
P/BV 1.931
EV/EBITDA 6.15
Цена ао 518.6
Число акций ао 0.0926 млрд
Сайт https://www.aartidrugs.co.in
Див.доход ао 0.1897
Дивиденд ао 1
Валюта inr
ISIN INE767A01016
Sector Health Care
Industry Pharmaceuticals
Валюта отчета inr
Изменение цены за день: -0.6855% (517.9)
Изменение цены за неделю: -1.9819% (524.75)
Изменение цены за месяц: -12.12% (585.3)
Изменение цены за 3 месяца: +1.9423% (504.55)
Изменение цены за полгода: +9.86% (468.2)
Изменение цены за год: -5.2% (542.55)
Изменение цены за 3 года: -16.59% (616.65)
Изменение цены за 5 лет: +14.33% (449.88)
Изменение цены с начала года: +2.63% (501.15)

Недооценка

Название Значение Оценка
P/S 1.2451 9
P/BV 2.84 6
P/E 20.33 7
EV/EBITDA 12.94 7
Итого: 6

Эффективность

Название Значение Оценка
ROA, % 6.87 2
ROE, % 13.95 4
Итого: 3.67

Дивиденды

Название Значение Оценка
Div yield, % 0.1897 0.48
DSI 0.9286 9.29
Итого: 1.86

Долг

Название Значение Оценка
Debt/EBITDA 1.9783 7
Итого: 7.2

Импульс роста

Название Значение Оценка
Доходность Revenue, % 40 6
Доходность Ebitda, % 18.46 3
Доходность EPS, % 22.91 4
Итого: 3.4



Руководитель Должность Оплата Год рождения
Mr. Prakash Moreshwar Patil Chairman, MD, CEO & Head of BR 27.65M 1947 (77 лет)
Mr. Harshit Manila Savla Joint MD & Executive Director 25.55M 1962 (62 года)
Mr. Adhish Prakash Patil CFO & COO N/A 1983 (41 год)
Mr. Rushikesh Vivek Deole Company Secretary & Compliance Officer N/A
Mr. Harit Pragji Shah Whole-Time Director 25.55M 1963 (61 год)
Mr. Uday Moreshwar Patil Whole-Time Director 3.19M 1963 (61 год)
Mr. Rashesh Chandrakant Gogri MD & Executive Director 25.55M 1974 (50 лет)
Mr. Dhanaji L. Kakade Vice President of Technical N/A
Mr. Vishwa Harshit Savla Managing Director of the Pinnacle Life Science Private Limited N/A

Адрес: India, Mumbai, Mahendra Industrial Estate - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.aartidrugs.co.in